Jounce Therapeutics Stock Price - JNCE

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 7.79 ▼ -0.00 (-0.00%)
Company Name Stock Ticker Symbol Market Type
Jounce Therapeutics Inc JNCE NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.185 2.43% 7.79 8.57 7.60 7.62 7.605 00:00:08
Bid Price Ask Price Spread Spread % News
7.57 9.08 1.51 16.63% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
9,017 1,671,927 $ 7.99 $ 13,363,293 742,594 2.66 - 9.80
Last Trade Time Type Quantity Stock Price Currency
19:23:07 1 $ 7.70 USD

Jounce Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 258.85M 33.23M $ -27.38M -0.83 3.40 32.90M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 1.00%

more financials information »

Jounce Therapeutics News

Loading Messages....

Latest JNCE Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical JNCE Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week4.889.804.817.572,713,1982.9159.63%
1 Month3.959.803.956.761,041,8733.8497.22%
3 Months3.599.802.796.17394,8474.20116.99%
6 Months4.399.802.795.61269,7073.4077.45%
1 Year4.339.802.665.26246,7363.4679.91%
3 Years18.0029.292.6611.14288,709-10.21-56.72%
5 Years18.0029.292.6611.14288,709-10.21-56.72%

Jounce Therapeutics Description

Jounce Therapeutics Inc is a clinical stage immunotherapy company. The company is dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company's strategy is to create immunotherapies targeting a variety of the diverse cellular components of the immune system, as well as non-immune cells resident within the tumor, all of which can vary greatly among tumors within and across indications. This may provide benefit to patients with tumors across the spectrum from highly inflamed, or hot, to poorly inflamed, or cold, and especially those not well served by current therapies. Its lead product candidate, JTX-2011, is a clinical stage monoclonal antibody.

Your Recent History
Jounce The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.